Haleon plc (HLN) News
Market Cap: $46.37B
Avg Volume: 11.55M
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Haleon shares hit by weaker US vitamin sales
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 1% after the toothpaste and painkillers maker reported slightly stronger first-quarter growth than expected but saw a weaker performance than expected from its vitamins, minerals and supplements (VMS) arm in America. The FTSE 100 group posted a Q1 update showing 3.5% organic revenue growth, supported by positive contributions from all product categories and regions, beating an average City forecast of 3.3%.
proactiveinvestors.co.uk
Read More
Haleon reports lower first-quarter revenue hurt by a weaker flu season
British consumer healthcare group Haleon on Wednesday reported a 2.3% fall in its first-quarter revenue as sluggish demand for its cold and cough medicines outside of North America continued to weigh.
reuters.com
Read More
UK's Haleon takes full control of Chinese consumer healthcare venture
British consumer healthcare group Haleon said on Tuesday it has gained complete ownership of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake for about 1.62 billion yuan ($221.4 million).
reuters.com
Read More
Does defensive Haleon have a cure for the current market blues?
Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about recession risks and the fallout from Donald Trump's new tariff regime. Shares in the maker of household brands such as Sensodyne and Panadol, have been under pressure amid broader worries over US consumer demand and a tough comparison with last year's strong flu season.
proactiveinvestors.co.uk
Read More
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off
As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margins and further debt reduction on a net debt/adjusted EBITDA basis (now 2.8x from 4.0x) demonstrate financial strength in uncertain economic conditions. Robust dividend coverage (2.5x covered by earnings) with steady growth and the strategic streamlining of its portfolio highlights Haleon as a reliable defensive investment.
seekingalpha.com
Read More
Haleon buys £170m of shares as Pfizer offloads final stake
Haleon PLC (LSE:HLN, NYSE:HLN) has bought roughly £170 million of its shares back from former parent company Pfizer Inc (NYSE:PFE, ETR:PFE). The FTSE 100-listed maker of toothpaste and vitamins paid 385p per share for the off-market purchase, which is part of a previous agreement when Haleon was spun out in 2022 that its former parent companies, GSK being the other, would eventually cut their stakes.
proactiveinvestors.co.uk
Read More
Pfizer sells entire Haleon stake for $3.24 billion
Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday.
reuters.com
Read More
Pfizer to dispose of entire Haleon stake
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
reuters.com
Read More
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year.
seekingalpha.com
Read More
Haleon: Growing Profits And Dividend
I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices.
seekingalpha.com
Read More
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday.
benzinga.com
Read More
Haleon CEO: We're relatively low-exposed to tariffs
Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results
youtube.com
Read More
Haleon figures meet expectations; but analysts and investors wanted more
Haleon PLC's (LSE:HLN, NYSE:HLN) prelims have reassured investors, with earnings per share (EPS) beating expectations by 6% in the second half of 2024, according to analysts - although the shares succumbed to a bout of profit taking in their wake. The consumer health giant reported 5% organic growth for the year, slightly ahead of market forecasts, Stifel said.
proactiveinvestors.co.uk
Read More
Haleon plc (HLN) Q4 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q4 2024 Earnings Conference Call February 27, 2025 4:00 AM ET Company Participants Jo Russell - Head-Investor Relations Brian McNamara - Chief Executive Officer Dawn Allen - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS David Hayes - Jefferies Rashad Kawan - Morgan Stanley Chris Pitcher - Redburn Tom Sykes - Deutsche Bank Jo Russell Good morning, everyone. Welcome to Haleon's Full Year 2024 Q&A call.
seekingalpha.com
Read More
Haleon: Investors unimpressed by growth target and £500m buyback as shares slide 3.2%
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.2% in early trading as investors saw little in the results to justify further gains at current valuations. While full-year sales and profits met expectations, analysts noted a lack of clear catalysts.
proactiveinvestors.co.uk
Read More
Haleon results could provide tonic for investor anxiety, says Barclays
When Haleon PLC (LSE:HLN, NYSE:HLN) reports results on Thursday, 27 February, Barclays expects its sales of painkillers to have offset the "well known headwind" from a weak start to the cold and flu season in the final quarter of 2024. Analysts at the bank said that earnings delivery and profit margin expansion are the main areas of focus for investors in the FTSE 100 consumer health products group too, while Futura Medical investors are likely to be keeping an eye out for news on the Eroxon collaboration.
proactiveinvestors.co.uk
Read More
Haleon to invest $54 mln in US R&D centre to boost product innovation
Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.
reuters.com
Read More
AHCO vs. HLN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Read More
Pfizer to further reduce stake in Haleon through share sale
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building process targeting institutional investors. Currently holding 15% of the Panadol maker, Pfizer expects to reduce its interest to about 7.3 per cent upon completion.
proactiveinvestors.co.uk
Read More
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
wsj.com
Read More
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.
reuters.com
Read More
TUMS Teams Up with DraftKings to Launch TUMS Fantasy Foodball Pool, Making Gameday Food Dreams a Reality
Fans can draft their top food and drink picks for a free shot at winning a share of $40,000 in total cash prizes WARREN, N.J. , Jan. 9, 2025 /PRNewswire/ -- As hundreds of millions prepare to tune into the biggest day in football, a new survey from TUMS has revealed that 1 in 4 viewers will be focused on the real MVP: the food.
prnewswire.com
Read More
Haleon: Guidance Implies Uncertainty Around Flu Season
Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3.
seekingalpha.com
Read More
Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation
WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024.
prnewswire.com
Read More
Dividend Income: Lanny's October 2024 Summary
Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, such as MDU Resources and Haleon.
seekingalpha.com
Read More
Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising
Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy
globenewswire.com
Read More
Haleon plc (HLN) Q3 2024 Sales Call Transcript
Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.
seekingalpha.com
Read More
Panadol maker Haleon takes hit from currency headwinds
Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.
proactiveinvestors.co.uk
Read More
Haleon reports marginal decline in third-quarter revenue
Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.
reuters.com
Read More
Haleon gets target hike as UBS raises 'forever' sales target
Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.
proactiveinvestors.co.uk
Read More
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
proactiveinvestors.co.uk
Read More
HLN or PODD: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
zacks.com
Read More
Haleon's buy rating restated after Pfizer cuts down stake
UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
proactiveinvestors.co.uk
Read More
Haleon buys back some shares as Pfizer sells down stake
Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
proactiveinvestors.co.uk
Read More
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
reuters.com
Read More
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
reuters.com
Read More
Sensodyne maker Haleon to raise stake in China JV
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
reuters.com
Read More
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem
globenewswire.com
Read More
Haleon lays out pricing for £1bn bond offering
Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.
proactiveinvestors.co.uk
Read More
Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024 WARREN, N.J. , Sept. 3, 2024 /PRNewswire/ -- Eroxon® , the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.
prnewswire.com
Read More
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future.
seekingalpha.com
Read More
Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off
While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend. Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.
proactiveinvestors.co.uk
Read More
Haleon a rare riser on tough day as Deutsche Bank hilts resilience
Haleon PLC (LSE:HLN, NYSE:HLN) interim results showed its resilience and dependability in very tough markets, suggests Deutsche Bank adding it deserves a higher rating. “The stock has been strong into results and the positive margin performance, along with some low season improvement in respiratory sell-out, is supporting the stock.
proactiveinvestors.co.uk
Read More
Haleon plc (HLN) Q2 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank you for joining us for the Haleon 2024 Half Year Results Q&A.
seekingalpha.com
Read More
Haleon ups profit guidance as power brands deliver
Haleon upped its forecast for profit growth this year after a strong performance from its power brands Sensodyne, parodontax and Centrum in the first six months. The consumer brands giant now expects organic profits to rise by a ‘high single-digit percentage', compared to previous guidance of ‘ahead of' the revenue forecast of 4-6%.
proactiveinvestors.co.uk
Read More
Futura Medical: Haleon ready launch Eroxon in the US before the year-end
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a boost from its blue-chip partner Haleon PLC (LSE:HLN, NYSE:HLN) on the timing of the US roll-out of Eroxon, Futura's fast-acting gel for erectile dysfunction. In its results statement earlier Thursday, the consumer products giant said Eroxon would be available Stateside before the year-end.
proactiveinvestors.co.uk
Read More
Haleon sees high single-digit growth for annual organic operating profit
Consumer healthcare firm Haleon on Thursday forecast high single-digit growth for its 2024 organic operating profit, after it posted a 4% rise in half-year pre-tax earnings amid strong demand for its oral care products and vitamins.
reuters.com
Read More
HLN vs. LMAT: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
zacks.com
Read More
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).
zacks.com
Read More
Haleon to quieten 'noise' with latest update, broker suggests
Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility' this year, suggests broker Jefferies. From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.
proactiveinvestors.co.uk
Read More
Haleon to sell nicotine replacement therapy business outside US for $633 mln
British consumer healthcare company Haleon said on Wednesday it would sell its nicotine replacement therapy business outside the United States to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million).
reuters.com
Read More
Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition
BOSTON , June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (LSE / NYSE: HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company.
prnewswire.com
Read More
GSK confirms exit of Haleon stake for £3.9 billion
GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.
proactiveinvestors.co.uk
Read More
GSK raises $1.5 bln from offloading Haleon stake at a discount
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
reuters.com
Read More
GSK intends to sell its remaining stake in Haleon
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
reuters.com
Read More
Haleon faces first short seller in Marshall Wallace
Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100 healthcare company, has seen £150 million of its shares shorted by Marshall Wace, the hedge fund. It represents the first time a short-seller of Haleon has made its position known since the company was spun out by pharma giant GSK two years ago.
proactiveinvestors.co.uk
Read More
Haleon plc (HLN) Q1 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q1 2024 Earnings Conference Call May 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Head, Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Rashad Kawan - Morgan Stanley Guillaume Delmas - UBS David Hayes - Jefferies Iain Simpson - Barclays Bruno Monteyne - Bernstein Victoria Petrova - Bank of America Celine Pannuti - JPMorgan Tom Sykes - Deutsche Bank Mikheil Omanadze - BNP Paribas Exane Chris Pitcher - Redburn Operator Ladies and gentlemen, welcome to the Haleon Q1 2024 Trading Update Conference Call. I am Davin, the chorus call operator.
seekingalpha.com
Read More
Haleon revenues fall in first quarter
Advil and Sensodyne maker Haleon PLC (LSE:HLN, NYSE:HLN) kept its full-year outlook unchanged as it reported lower first-quarter revenue, though this was in line with expectations. Organic revenues were 3.0% higher than the same quarter last year, with sales volumes and product mix provided a negative contribution of 2%, held back by a weaker cold and flu season, offset by 5% price growth.
proactiveinvestors.co.uk
Read More
Haleon's first-quarter revenue misses expectations
Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a surge last year.
reuters.com
Read More
Haleon eyes job cuts as UK manufacturing site 'no longer viable'
News that Sensoyde toothpaste maker Haleon PLC (LSE:HLN, NYSE:HLN) could cut around 435 jobs as part of the shuttering of an oral products manufacturing site has lifted the shares 1.5%. The FTSE 100 group, which was spun out of GSK two years ago, is planning to close a site in Maidenhead in the next two years.
proactiveinvestors.com
Read More
Sensodyne-maker Haleon to shut UK manufacturing site, with more than 400 jobs hit
Consumer healthcare company Haleon is planning to shut down its manufacturing site in Britain by 2026, which will impact 435 jobs, a spokesperson told Reuters on Tuesday.
reuters.com
Read More
Haleon on course for sector leading earnings growth, analysts predict
Haleon is due to report its first-quarter earnings on 1 May with UBS upping its organic sales growth forecast to 3.2% from 3.0% previously. Comparatives are tough in Respiratory Health and Pain Relief but these will be offset by expected continued strong momentum in Oral Health, said the bank.
proactiveinvestors.co.uk
Read More
Haleon overhang can be gone in a year, suggests Barclays
One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker.
proactiveinvestors.co.uk
Read More
Pfizer upsizes Haleon stake sale
Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping roughly £2.4 billion compared to the £2 billion expected, after the public offering was upsized. The FTSE 100-listed consumer goods company said the US and international offer had been priced at £3.08 per ordinary share and $7.85 per American Depositary Shares.
proactiveinvestors.co.uk
Read More
Pfizer to sell down stake in Haleon
Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising over £2 billion (US$2.55bn). Haleon, a former consumer health joint venture between GSK and Pfizer that was spun out in 2022, aims to but £315 million of the shares, it said.
proactiveinvestors.co.uk
Read More
Consumer healthcare giant Haleon says Pfizer to cut stake to 24%
Consumer healthcare giant Haleon said on Monday that Pfizer will sell about 630 million of its shares in the company, reducing the US drugmaker's stake to about 24%.
reuters.com
Read More
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Products stocks are likely familiar with AdaptHealth Corp. (AHCO) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
Read More
Haleon building 'solid track record,' says Barclays
Haleon steadied the ship last week for consumer staples suppliers after a results shock from Reckitt Benckiser, according to analysts at Barclays. Indeed, Haleon is building a solid track record of organic growth and making rapid progress on deleverage and capital return, added the broker.
proactiveinvestors.co.uk
Read More
Haleon plc (HLN) Q4 2023 Earnings Call Transcript
Haleon plc (HLN) Q4 2023 Earnings Call Transcript
seekingalpha.com
Read More
Haleon Shares Rise 5%+ As Strong FY Results Drive Share Buyback Scheme
FTSE 100-listed Haleon's share price leapt in Thursday trading, as strong sales growth and debt reduction in 2023 prompted it to launch a share repurchase programme.
forbes.com
Read More
Haleon shares up 7% as it shrugs off mild cold and flu season and plans £500m buyback
Haleon PLC (LSE:HLN, NYSE:HLN), the purveyor of medicine cabinet staples such as Panadol and Advil, joined Reckitt Benckiser PLC in suffering the effects of a mild cold and flu season. This, and slackening demand from China, were blamed for what is expected to be a slow first quarter of the new financial year.
proactiveinvestors.com
Read More
Consumer health giant Haleon sees higher revenue in 2024 on sustained demand
Sensodyne toothpaste-maker Haleon said on Thursday it expected higher revenue in 2024, thanks to firm demand for its household products ranging from painkillers to multivitamins.
reuters.com
Read More
British Airways, Ocado and Haleon to set next week's pace
Scheduled company news is a little quieter after last week's rush of bank, mining and US tech updates, but there is still a decent stack of household names updating. Bunzl, the biggest company nobody has heard of, kicks off the week with British Airways owner IAG, GSK spin-off Haleon, Ocado and Pearson all due as well.
proactiveinvestors.com
Read More
Abreva Drops One-of-a-Kind Pair of Diamond Lips, Inspired by the Cold Sore Experience
The leader in cold sore relief will shine a light on the condition, rewarding one cold sore sufferer with the limited edition, sparkling accessory. WARREN, N.J.
prnewswire.com
Read More
Haleon garners mixed impressions from City analysts
Analysts are divided over fast-moving consumer goods big cap Haleon PLC (LSE:HLN, NYSE:HLN)'s prospects prior to the FTSE 100-listed firm's annual results next month. According to Jefferies, Haleon is well-positioned to exceed both its organic sales and operating profit growth forecasts, placing it at the higher end of its full-year guidance.
proactiveinvestors.com
Read More
Haleon to recall batches of some adult cough syrups due to contamination
Haleon is recalling some lots of its adult cough syrup Robitussin because of microbial contamination, the U.S. Food and Drug Administration (FDA) has said.
reuters.com
Read More
Haleon sells ChapStick brand in bid to relieve debt pile
Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare company, confirmed the sale of its lip balm brand ChapStick for US$430 million, a company statement revealed. Suave Brands, a portfolio company of Yellow Wood Partners, will also provide Haleon with a minority stake worth around US$80 million as part of the deal.
proactiveinvestors.com
Read More
Haleon to sell ChapStick to Yellow Wood for about $510 million
Britain's Haleon said it had agreed to sell lip balm brand ChapStick to a company owned by private equity firm Yellow Wood Partners for around $430 million in cash and a stake valued at around $80 million in the buyer.
reuters.com
Read More
Yellow Wood Partners Portfolio Company Suave Brands Company Acquires ChapStick from Haleon
BOSTON , Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (LSE / NYSE: HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals.
prnewswire.com
Read More
New Research Affirms the Positive Impact of Centrum Silver on Memory in Older Adults
A third study from the COSMOS trial, COSMOS-Clinic, demonstrates consistent findings that taking Centrum Silver multivitamin daily benefits memory among older adults. WARREN, N.J.
prnewswire.com
Read More
Haleon slides as forecasts trimmed ahead of full-year results
Haleon PLC (LSE:HLN, NYSE:HLN) was the biggest faller on the FTSE 100 on Wednesday morning after JPMorgan fired off a warning shot ahead of the Sensodyne and Panadol maker's annual results next month. Having delivered strong volumes versus sector peers in the consumer staples sector over the past two years, the investment bank now expects the top line to disappoint as the tailwinds that boosted its over-the-counter divisions abate.
proactiveinvestors.com
Read More
TUMS® Teams Up with DraftKings and Desus Nice to Launch TUMS® Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
TUMS® Prop Bites allows fans to decide which foods have won America's hearts and stomachs for a shot at a share of $10,000 prize pool WARREN, N.J. , Jan. 17, 2024 /PRNewswire/ -- In honor of the biggest day in football, TUMS® is collaborating with DraftKings to launch TUMS® Prop Bites, a first-of-its kind platform where fans can make their free food picks and see how they stack up against the rest of the nation for a shot to win cash prizes.
prnewswire.com
Read More
GSK nets £978m from Haleon share sale
GSK PLC (LSE:GSK, NYSE:GSK) said it completed the sale of 300 million shares in Haleon, the consumer health giant, netting £978 million, or $1.23 billion, in the process. The sum is around $200 million shy of the cash it is handing over to take over Aiolos Bio, the respiratory and inflammatory diseases specialists.
proactiveinvestors.com
Read More
GSK raises $1.24 bln from latest Haleon stake sale
British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon , cutting its shareholding to 4.2% in the world's largest standalone consumer healthcare firm.
reuters.com
Read More
GSK to sell 3.2% stake in spin-off Haleon
GSK will sell a 3.2% stake, or about 300 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Tuesday.
reuters.com
Read More
TUMS Partners with Designer Nik Bentel to Launch Limited Edition TUMS Bag to Fuse Food, Fashion and Heartburn Relief
The Official TUMS Bag is Available on Amazon and nikolasbentelstudio.com – Hurry, Before They Sell Out! WARREN, N.J.
prnewswire.com
Read More
3 cheap 'stock'-ing stuffers Wall Street is bullish on
Known for historically being the strongest month of the year for U.S. stocks, the Dow and S&P 500 both gained nearly 9% last month. The Nasdaq, almost 11%.
marketbeat.com
Read More
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.
zacks.com
Read More
Haleon's Long-Term Growth Prospects Look Healthy On Solid Macro Trends
Haleon is a leading consumer healthcare company operating in the OTC medication, vitamins, minerals & supplements, and oral health segments. The company's strong brand and product moat make it less susceptible to recession impact, and its geographic diversification provides a stable financial base for growth. Despite challenges in the North American market and ongoing economic uncertainty, Haleon is trading at a significantly undervalued level with a potential upside of c.20%.
seekingalpha.com
Read More
Dividend Income Summary: Lanny's October 2023 Summary
Growing dividend income takes time and consistency. The Fed paused a rate hike in September and will likely remain in a holding pattern for November, with a modest chance of an increase in December. Increase passive income by consistently investing in the market and letting dividend reinvestment do the trick.
seekingalpha.com
Read More
Health exclusion affects more than three in five people globally
Phase two of Economist Impact's Health Inclusivity Index, supported by Haleon, measures experience of health inclusion across 42,000 people in 40 countries Health inclusivity scores fall worldwide with addition of lived experience data, exposing glaring policy-practice gap in wealthy countries 66% of survey respondents experience barriers to health inclusion, with the most vulnerable worst affected Index reveals stark generational divide with Gen Z and Millennials experiencing greater barriers to access and higher levels of discrimination LONDON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- More than three in five people worldwide experience health exclusion, with vulnerable and younger populations the worst affected, according to phase two of the global Health Inclusivity Index from Economist Impact, supported by consumer health company Haleon. This year's study – which measures the extent and experience of health inclusion across 40 countries and 42,000 people – revealed that 66% of those surveyed face at least one barrier in accessing healthcare services.
globenewswire.com
Read More
UK falls to third place in global Health Inclusivity Index
More than three in five (63%) people in the UK experience barriers to health inclusion People in UK, Canada and France face the longest waiting times to see a GP Health inclusivity scores fall worldwide with addition of lived experience data in Economist Impact's Health Inclusivity Index, supported by Haleon - exposing glaring policy-practice gap in wealthy countries LONDON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- More than three in five (63%) people in the UK experience health exclusion according to phase two of the Economist Impact's Health Inclusivity Index, released today. The Index - which measures the extent and experience of health inclusion across 40 countries and 42,000 people worldwide - reveals that the UK's score has fallen by 13% this year, slipping from first to third place in the global rankings.
globenewswire.com
Read More
Haleon: A Stable Pick
Haleon sells health products internationally with stable operations and modest growth through a good performance in oral health products, and growth in Asia Pacific. The company's financials have remained solid with stable revenue increases and high EBIT margins. The stock seems to be priced for the good financials - I don't see significant upside or downside for the stock at the moment.
seekingalpha.com
Read More
Britain falls from top spot in Economist Impact's latest Health Inclusivity Index
The second phase of the index, supported by Haleon, assesses governments' efforts across 40 countries to ensure that good health is accessible to all individuals LONDON , Nov. 20, 2023 /PRNewswire/ -- Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, today launched phase two of the Health Inclusivity Index , supported by Haleon (LSE / NYSE: HLN), a global leader in consumer health. This phase's results show health inclusivity falling worldwide, and notably Britain falling from its top spot in phase one.
prnewswire.com
Read More
The Investment Case For Haleon: Steady Shareholder Value Accumulation
Haleon plc is a promising company in the personal care products sector, with a low beta and cheap valuation. The company operates globally and has leading brands in oral health, painkillers, and vitamins. Haleon's ownership structure is interconnected with Pfizer and GSK, but divestitures could increase competitive pressures.
seekingalpha.com
Read More
Haleon down as sales and earnings marginally undershoot - maintains full-year outlook
Haleon PLC (LSE:HLN, NYSE:HLN)'s stock took a 2.6% hit in early trading, erasing roughly £800 million in market value, following the company's third-quarter revenue and profit report that fell short of market expectations. For the quarter ending September 30, Haleon reported a 5% organic increase in revenue, totalling £2.79 billion, slightly below the anticipated £2.83 billion.
proactiveinvestors.com
Read More
Advil maker Haleon's quarterly revenue rises on price hikes, strong demand
Consumer healthcare company Haleon posted higher third-quarter revenue and stuck by its full-year forecasts on Thursday, helped by price hikes and resilient demand for its painkillers, cold and flu tablets, and oral health products.
reuters.com
Read More
Haleon update expected to be reassuringly steady
Haleon's third-quarter update won't be game-changing but will support a longer-term debt reduction thesis, suggests Citi. Organic sales growth should be 5.2% prices +4.7%), says the US bank, with a likely 3.9% increase forecast for the fourth quarter with flu volumes the drag.
proactiveinvestors.com
Read More